immune response , ein siegerpferd!!! - 500 Beiträge pro Seite

[HerrLose]

habe mir immune response ins depot gepackt , nachdem die
empfelungen von juchu und thieme mich überzeugt haben.
finde leider nicht die homepage der biotechfirma .
wer hat sie in petto.

wer reiht sich ein ?

tschöle

[kufeller]

Ich habe sie auch seit der Empfehlung von Juchu.de und denke auch das noch einiges an Potential da ist.
Die Homepageadresse habe ich leider auch nicht.

[OesiStockpicker]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[justizia]

www.imnr.com

[Powerbeetle]

Hallo zusammen!

an diesem Board bin ich neu, wobei ich aber allgemein
nicht sehr viel schreibe.

Hilfestellung:

www.imnr.com

Laßt Euch im E-Mail Verteiler registrieren,(kostenfrei)
dann seid Ihr immer auf dem laufenden.

Viel Spaß noch mit der Aktie.

Ich hoffe, Ihr seid auch in Calypte investiert???!!!

Gruß
PB

[traveljoe]

Ich finde bei Juchu nichts über IMNR, und was hat Thieme gesagt,
wer gibt mir einen Tipp??

Danke

[Risky]

Interessantes Unternehmen, da Pipline prall gefüllt.Heute bereits (Nasdaq) 7,69 % plus (18:40 Uhr).

[HerrLose]

ich finde die produkte ,die in der pipiline stecken ,decken genau
die krankheiten ab,die am gravierendsten auf der welt wüten.
ergo: hier ist ordenlich profit zu machen , aber in erster linie natürlich der menschheit zu helfen.

wie seht ihr das?


HIV. The Company`s most advanced therapy under development, REMUNE, is based on an approach first proposed by the late Dr. Jonas Salk, a co-founder of the Company. REMUNE is an immune-based therapy intended to treat HIV-infected individuals and prevent or delay the progression to Acquired Immune Deficiency Syndrome ("AIDS"). REMUNE is designed to stimulate an HIV-infected individual`s immune system to attack HIV and can be used alone or in combination with existing antiviral drug therapies for HIV. The Company believes that clinical trials conducted since 1987 have suggested that REMUNE is safe and well tolerated and may have a favorable impact on multiple markers of HIV disease progression including viral burden, CD4 cell count, HIV-specific cell-mediated immunity, antibody production and weight gain. In March 1996, the Company initiated a pivotal Phase III clinical trial for REMUNE. This clinical trial, involving 2,500 HIV-infected individuals at 74 clinical centers in the United States, was fully enrolled in May 1997. Subsequent to the start of the Phase III clinical trial, the United States Food and Drug Administration ("FDA") granted expanded access approval for those individuals who are ineligible to enroll in this trial. The Company expects to dedicate a substantial portion of its resources to the REMUNE program.

The Company is also conducting trials in additional patient populations. In March 1996, the Company`s licensee, Trinity Medical Group Co., Ltd. ("Trinity") of Bangkok, Thailand, initiated a Phase II clinical trial with REMUNE in Thailand. In May 1996, the Company initiated a Phase I clinical trial with the National Institutes of Health ("NIH") to treat HIV-infected children. In October 1996, the Company initiated a Phase II combination drug trial in Spain. Finally, in February 1997, the Company, in conjunction with Glaxo Wellcome and Merck & Co., initiated a Phase II combination drug trial in the U.S. Glaxo is providing AZT and 3TC and Merck is providing its protease inhibitor, Crixivan.

Autoimmune Disease. Immune Response is using its proprietary autoimmune disease technology to develop treatments for certain autoimmune diseases, particularly rheumatoid arthritis, psoriasis, and multiple sclerosis. Currently approved therapies treat only the symptoms of these diseases. The Company`s technology is designed to inhibit the destructive activity of the specific autoreactive T cells that the Company believes cause each disease by generating an immune response against the unique markers on the autoreactive T cells. In January 1997, the Company announced the results from both the rheumatoid arthritis and psoriasis Phase II clinical trials. The Company believes that the results for rheumatoid arthritis demonstrated safety and a statistically significant clinical improvement in disease condition using the American College of Rheumatology guidelines (ACR 20 criteria). The Company believes that the results for psoriasis were safe and patients in all groups improved during the course of the trial. In addition, the Company has completed a Phase I clinical trial for multiple sclerosis.

Gene Therapy. The Company`s proprietary GeneDrug technology under development is designed to replace missing or defective genes to treat disease. This technology uses a unique system intended to deliver genes specifically to the liver after a single intravenous injection. In preclinical studies, a potential GeneDrug product was successfully used for Factor VIII to produce therapeutic levels of this blood clotting factor for 60 days. If similar results can be obtained in humans, the Company believes that this therapy could provide significant advantages over the current treatments for hemophilia. Additionally, a potential GeneDrug for interferon-alpha ("IFN") also has been used in preclinical studies to induce production of significant levels of IFN within the liver as a potential treatment for hepatitis.

Cancer. The Company is also developing new therapies for the treatment of cancer. These technologies are designed (i) to increase immune system recognition of cancers, (ii) to inhibit cancer evasion of the immune system, and (iii) to sensitize cancer to conventional therapies. In December 1996, the Company completed a Phase I clinical trial in colon cancer. The Company believes the results from this trial indicated the therapy was safe and patients demonstrated strong positive skin tests with 3-5 fold increases in precursor frequency of tumor reactive T cells. The Company initiated a Phase Ib clinical trial for colon cancer in September 1998 and plans to start a Phase I clinical trial for brain cancer in the fourth quarter of 1999.

[oberfuchs]

Hallo
IMNR: Neue Patente in der Pipline. Die Party geht weiter!

Gruß oberfuchs

[109]

.